Hospital and biomedical company join together for better diabetic care
New Britain [October 18 2006] -
Everybody is different—and people respond differently to the same medications. But what if you knew, in advance, which medicines are likely to be most effective for you, based on genetics and your personal DNA profile?
That’s the idea behind an exciting new partnership announced today between The Hospital of Central Connecticut, and Genomas, Inc.
The Hospital and Genomas will work together to develop new DNA diagnostic systems to help select the right drugs and treatments for people with diabetes. This includes management of some of the related—and often extremely debilitating--conditions associated with advanced diabetes.
“This exciting new partnership is a concrete example of our commitment to bring the most advanced and sophisticated medical care to the people of Central Connecticut through innovative and groundbreaking research,” said Laurence A. Tanner, president and chief executive officer of The Hospital of Central Connecticut. “This is also an affirmation of our longstanding commitment to offer world-class care to people with diabetes.”
Genomas and the hospital will jointly develop DNA -guided systems for managing diabetes. These systems predict the risk of developing liver injury, weight gain, and other adverse metabolic reactions to drugs used to treat diabetes.
“The partnership with the hospital allows us to bring DNA-guided medicine to patients with diabetes. It is essential work, because the medications for which we are developing personalized prescription systems are being used more often, and at higher doses,”
said Gualberto Ruano, president of Genomas.
The partnership also furthers the hospital’s commitment to provide the “gold standard of care to people with diabetes,” said Dr. Steven D. Hanks, the hospital’s senior vice president of medical affairs and chief medical officer. A decade ago, the hospital, then known as New Britain General, became affiliated with the Joslin Diabetes Center in Boston, a world leader in diabetes treatment, research and education.
As a Joslin affiliate, the Hospital strives to meet rigorous standards of care for people with diabetes, and to help them develop skills to manage their blood sugar, avoid complications and maintain better health throughout their lifetime.
Dr. Hanks called the Genomas partnership “the logical next step.”
Genomas Inc. is a biomedical company advancing personalized health with revolutionary PhyzioType™ medical management systems to treat metabolic conditions. This includes metabolic conditions induced by drugs and obesity, in cardiovascular and psychiatric medicine and now diabetes management. Genomas is located in Hartford on the campus of Hartford Hospital.
The Hospital of Central Connecticut was formed Oct. 1 by the merger of New Britain General and Bradley Memorial Hospitals. With campuses in New Britain and Southington, it is a 414-bed, 32-bassinet acute-care teaching hospital affiliated with the University of Connecticut School of Medicine. The Hospital of Central Connecticut provides comprehensive inpatient and outpatient healthcare services in medicine, surgery, and a wide variety of specialties.
Contact: Helayne Lightstone, (860) 224-5470
HCC Corporate Communications
(860) 224-5695 •
Fax (860) 224-5779